Biotechnology Innovation Organization (BIO)
1225 Eye Street, NW
About Biotechnology Innovation Organization (BIO)
The Biotechnology Innovation Organization (BIO) is the largest trade organization to serve and represent the emerging biotechnology industry in the United States and around the globe. The organization's leadership and service-oriented guidance have helped advance the industry and bring the benefits of biotechnology to the people of the world.
As the leading voice for the biotechnology industry, BIO represents companies of all sizes engaged in the development of products and services in the areas of agriculture, biomedicine, diagnostics, food, energy and environmental applications. Though biotechnology's future is bright, the industry's success will depend on the commitment, energy and direction of the group that helps guide its growth. BIO is a vital forum and an invaluable focal point to bring together the resources and expertise to meet critical challenges and serve the needs of its members.
3299 articles with Biotechnology Innovation Organization (BIO)
There is a concept held dear by many that there is strength in diversity. At South San Francisco-based Genentech, that is a concept also embraced by Sara Kenkare-Mitra, senior vice president of development sciences.
After Health and Human Services Secretary Alex Azar, a former executive with Eli Lilly, unveiled a pricing reform that would allow pharma companies to end the rebate system and pass those savings directly to consumers, leaders from across the pharma industry are offering early support for the pro...
"There is too much at stake for our elected leaders to place short-term political interests ahead of the long-term well-being of America's patients."
Last week HHS floated a plan that would allow companies to pass rebates of 26 to 30 percent of a drug’s list price directly to patients in order to be reflected in what consumers pay at the pharmacy counter.
BIO’s President and CEO Jim Greenwood issued the following statement today after the Trump administration released a proposed rule that would alter safe harbor policies under the federal anti-kickback statute:
It’s no secret that the pharmaceutical industry spends a significant amount of money lobbying state and federal governments to gain leverage that will benefit individual companies and the industry overall.
According to U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb, less than two percent of Americans use biologics, but they account for 40 percent of total spending on prescription drugs.
In writing literally hundreds of stories this year, two BioSpace writers, Alex Keown and Mark Terry, found certain stories particularly intriguing or impactful. Some of those were such big topics that they were covered over a series of stories. Looking back at 2018, here are their Top 10.
Biotechnology Innovation Organization, President & CEO James C. Greenwood issued a statement on the Hatch-Waxman Integrity Act of 2018
Bill includes key provisions that foster biotech innovation; support rural communities; and strengthen America’s bio-based economy
The idea of throwing Big Pharma under the bus in order to protect innovative biotech companies sparked a robust conversation at the seventh annual Forbes Healthcare Summit.
This week, the House of Representatives plans to take up a tax and oversight package (H.R. 88) which includes a provision that would protect investments in start-ups from inadvertently triggering the net operating loss (NOL) limitations under Section 382 of the tax code.
The Biotechnology Innovation Organization (BIO) today announced preliminary programing for the upcoming BIO CEO & Investor Conference to be held February 11-12, 2019 in New York City.
The Biotechnology Industry Organization (BIO) published the fifth edition of the Building the Bioeconomy report recently. The report studied 28 different indicators and provided analysis and insight into the biotech environment for 33 countries. The goal of the report is to determine how successf...
Cellect Biotechnology Ltd. announced today its CEO Dr. Shai Yarkoni will present at the 24th Annual Bio Europe Conference.
Bill reforms tax rules that currently penalize investment in job creation, innovation
BIO Applauds House Passage of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Legislation will strengthen pipeline of medical countermeasures against serious public health threats
CODA Biotherapeutics launched in South San Francisco with a $19 million Series A financing.
The Biotechnology Innovation Organization (BIO) today unveiled programming for its upcoming BIO Investor Forum to be held October 17-18 at the Westin St. Francis Hotel in San Francisco.
BIOplus 2018 : Game-changing insights and the latest research on immune checkpoint inhibitors for cancer therapy from GlobalData’s Fern Barkalow
BIOplus 2018 will reveal the latest global intelligence in biotech and healthcare developments.